Evaluation of therapeutic effects of a pomegranate preparation in patients with hepatic cirrhosis

Phase 2

• Conditions: liver cirrhosis.; Other cirrhosis of liver; K74.69

• Registration Number: IRCT20191130045548N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 August 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Patients with hepatic cirrhosis

Exclusion Criteria

Non-cirrhotic patients
Cirrhotic patients who have progressed to liver transplantation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Model for End-Stage Liver Disease (MELD) score. Timepoint: The beginning of the study (or before administration of pomegranate preparation) and two months after (two months after administration of the preparation). Method of measurement: ALT (Alanin Transaminase), AST (Aspartate Aminotransferase), ALP ( Alkaline Phosphatase), INR ( International Normalized Ratio), Albumin, creatinine, bilirubin, also clinical investigations for presence of ascites and hepatic encephalopathy and calculation of MELD score Model for End-Stage Liver Disease.